127 related articles for article (PubMed ID: 10211093)
21. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
Stordal B; Pavlakis N; Davey R
Cancer Treat Rev; 2007 Jun; 33(4):347-57. PubMed ID: 17383100
[TBL] [Abstract][Full Text] [Related]
22. [Pt(O,O'-acac)(γ-acac)(DMS)] versus cisplatin: apoptotic effects in B50 neuroblastoma cells.
Grimaldi M; Santin G; Insolia V; Dal Bo V; Piccolini VM; Veneroni P; Barni S; Verri M; De Pascali SA; Fanizzi FP; Bernocchi G; Bottone MG
Histochem Cell Biol; 2016 May; 145(5):587-601. PubMed ID: 26748644
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin (L-OHP): a new reality in colorectal cancer.
Bleiberg H
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611
[TBL] [Abstract][Full Text] [Related]
24. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Liu L; Li Y; Xiong X; Qi K; Zhang C; Fang J; Guo H
Int J Oncol; 2016 Dec; 49(6):2319-2330. PubMed ID: 27840903
[TBL] [Abstract][Full Text] [Related]
25. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
Stordal B; Peters G; Davey R
Genes Chromosomes Cancer; 2006 Dec; 45(12):1094-105. PubMed ID: 16967470
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines.
Riccardi A; Servidei T; Tornesello A; Puggioni P; Mastrangelo S; Rumi C; Riccardi R
Eur J Cancer; 1995; 31A(4):494-9. PubMed ID: 7576952
[TBL] [Abstract][Full Text] [Related]
27. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
28. The cellular pharmacology of oxaliplatin resistance.
Mishima M; Samimi G; Kondo A; Lin X; Howell SB
Eur J Cancer; 2002 Jul; 38(10):1405-12. PubMed ID: 12091073
[TBL] [Abstract][Full Text] [Related]
29. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.
Saintas E; Abrahams L; Ahmad GT; Ajakaiye AM; AlHumaidi AS; Ashmore-Harris C; Clark I; Dura UK; Fixmer CN; Ike-Morris C; Mato Prado M; Mccullough D; Mishra S; Schöler KM; Timur H; Williamson MD; Alatsatianos M; Bahsoun B; Blackburn E; Hogwood CE; Lithgow PE; Rowe M; Yiangou L; Rothweiler F; Cinatl J; Zehner R; Baines AJ; Garrett MD; Gourlay CW; Griffin DK; Gullick WJ; Hargreaves E; Howard MJ; Lloyd DR; Rossman JS; Smales CM; Tsaousis AD; von der Haar T; Wass MN; Michaelis M
PLoS One; 2017; 12(2):e0172140. PubMed ID: 28192521
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
31. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.
Faivre S; Chan D; Salinas R; Woynarowska B; Woynarowski JM
Biochem Pharmacol; 2003 Jul; 66(2):225-37. PubMed ID: 12826265
[TBL] [Abstract][Full Text] [Related]
32. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
34. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
35. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
36. Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity.
Bierau J; Van Gennip AH; Leen R; Helleman J; Caron HN; Van Kuilenburg AB
Int J Cancer; 2003 Jan; 103(3):387-92. PubMed ID: 12471622
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death.
Tassone P; Tagliaferri P; Galea E; Palmieri C; Bonelli P; Martelli ML; Tuccillo F; Turco MC; Venuta S
Eur J Cancer; 2002 May; 38(8):1141-7. PubMed ID: 12008204
[TBL] [Abstract][Full Text] [Related]
38. A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells.
Rangone B; Ferrari B; Astesana V; Masiello I; Veneroni P; Zanellato I; Osella D; Bottone MG
Life Sci; 2018 Oct; 210():166-176. PubMed ID: 30144454
[TBL] [Abstract][Full Text] [Related]
39. Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells.
Piacentini M; Fesus L; Melino G
FEBS Lett; 1993 Apr; 320(2):150-4. PubMed ID: 8096193
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin or cisplatin?
Pinkerton CR; Lewis IJ; Pearson AD; Stevens MC; Barnes J
Lancet; 1989 Jul; 2(8655):161. PubMed ID: 2567925
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
